NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE …
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
LUND, SE / ACCESS Newswire / September 8, 2025 / Alligator Bioscience (STO:ATORX) – Alligator Bioscience AB (“Alligator Bioscience” or the “Company”) hereby announces that the Company has renegotiated the outstanding loan from Fenja Capital II A/S (“Fenja Capital”), which originally was raised in June 2024 and subsequently renegotiated in November 2024 and May 2025. As a result of the renegotiation, Fenja Capital agrees to waive the previous condition that 50 per cent of all net proceeds from the exercise of warrants series TO 13 (“TO 13”) shall be used for amortization of the outstanding loan. Furthermore, the maturity date of the loan has been extended from 30 September to 31 December 2025. Through the renegotiation, Fenja Capital can choose to convert all or part of the outstanding nominal amount under the loan into new ordinary shares in the Company through set-off. In addition to the renegotiation, the Company announces that it has received subscription intentions in the ongoing exercise of TO 13 from the Company’s Chairman of the Board of Directors, CEO and CFO, encompassing all of their respective TO 13 and amounting in total to approximately SEK 0.2 million.
Renegotiation of outstanding loan
Alligator Bioscience carried out a rights issue of units during December 2024 – February 2025 (the “Rights Issue”). In connection with the Rights Issue, as announced in the Company’s press release from 2 December 2024, the Company renegotiated the outstanding loan and convertibles from Fenja Capital, which were originally raised in June 2024, with a new loan being arranged thereafter (the “New Loan”). The New Loan was thereafter renegotiated in May 2025 in connection with the exercise of the warrants series TO 12. For further information on the New Loan, please refer to the Company’s press releases from 2 December 2024 and 9 May 2025, respectively.
Read more on wallstreet:online
